JAWAHARLAL NEHRU TECHNOLOGICAL UNIVERSITY HYDERABAD

JAWAHARLAL NEHRU TECHNOLOGICAL UNIVERSITY HYDERABAD B.Pharmacy IV Year PHARMACOVIGILANCE Previous Question Paper (June/July - 2024 - R17)

B.Pharmacy | IV Year | I | R17 | June/July - 2024

Answer PaperPaper Code: 247AGMaximum Marks: 75Time: 3 Hours

Note: i) Question paper consists of Part A, Part B. ii) Part A is compulsory, which carries 25 marks. In Part A, Answer all questions. iii) In Part B, Answer any one question from each unit. Each question carries 10 marks and may have a, b as sub questions.

Part A

125 marks
a

Define unexpected Adverse drug reaction.

2 marks

Answer

An unexpected adverse drug reaction is an adverse reaction, the nature, severity, or outcome of which is not consistent with the applicable product information (such as the Investigator's Brochure for an unapproved drug or the Summary of Product Characteristics for a marketed drug).

b

Outline the role of WHO collaborating centre.

3 marks

Answer

The WHO Collaborating Centre for International Drug Monitoring (Uppsala Monitoring Centre) plays a key role in:

  • Maintaining the global database (VigiBase) of individual case safety reports.
  • Developing standardized terminology and coding systems like MedDRA and WHO-ART.
  • Providing technical support, training, and guidance to national pharmacovigilance centers to strengthen global drug safety monitoring.
c

Define daily defined doses.

2 marks

Answer

Sign in to view the complete answer paper.

d

Name the design concepts for Standard MedDRA Queries content.

3 marks

Answer

Sign in to view the complete answer paper.

e

Define vaccine pharmacovigilance.

2 marks

Answer

Sign in to view the complete answer paper.

f

Classify Adverse events following immunization.

3 marks

Answer

Sign in to view the complete answer paper.

g

Define Periodic safety updates reports.

2 marks

Answer

Sign in to view the complete answer paper.

h

List out the objectives of PSURs.

3 marks

Answer

Sign in to view the complete answer paper.

i

Define pharmacogenomics.

2 marks

Answer

Sign in to view the complete answer paper.

j

Outline the principle guiding Pediatric product development.

3 marks

Answer

Sign in to view the complete answer paper.

Part B

210 marks
a

Explain the classification of ADR.

5 marks

Answer

Sign in to view the complete answer paper.

b

List out what to report for ADR.

5 marks

Answer

Sign in to view the complete answer paper.

OR
310 marks
a

List out any 10 basic terminologies involved in adverse medication related events with definitions.

5 marks

Answer

Sign in to view the complete answer paper.

b

Explain the management adverse drug reactions.

5 marks

Answer

Sign in to view the complete answer paper.

410 marks
a

List out the system-organ classes and codes.

5 marks

Answer

Sign in to view the complete answer paper.

b

Explain about EUDRAVIIGILANCE Medical product dictionary.

5 marks

Answer

Sign in to view the complete answer paper.

OR
510 marks
a

Explain basic drug information sources.

5 marks

Answer

Sign in to view the complete answer paper.

b

Develop the plan for the establishment of pharmacovigilance system in hospital.

5 marks

Answer

Sign in to view the complete answer paper.

610 marks
a

What is Vaccine safety surveillance? Explain in detail different types of pharmacovigilance methods used for passive and active surveillance.

5 marks

Answer

Sign in to view the complete answer paper.

b

Explain briefly about cross sectional study.

5 marks

Answer

Sign in to view the complete answer paper.

OR
710 marks
a

Explain briefly about case control study and cohort study.

5 marks

Answer

Sign in to view the complete answer paper.

b

Explain briefly about stimulated reporting.

5 marks

Answer

Sign in to view the complete answer paper.

810 marks
a

Explain about pre-clinical phase.

5 marks

Answer

Sign in to view the complete answer paper.

b

What is the organization and objective of ICH guidelines in Pharmacovigilance? Explain in detail good clinical practices in Pharmacovigilance studies.

5 marks

Answer

Sign in to view the complete answer paper.

OR
910 marks
a

Discuss briefly about pharmacovigilance plan.

5 marks

Answer

Sign in to view the complete answer paper.

b

Summarize PSUD.

5 marks

Answer

Sign in to view the complete answer paper.

1010 marks
a

Discuss about approaches for identification of causative gene.

5 marks

Answer

Sign in to view the complete answer paper.

b

Explain about drug metabolizing enzyme.

5 marks

Answer

Sign in to view the complete answer paper.

OR
1110 marks
a

Elaborate about drug safety in lactation.

5 marks

Answer

Sign in to view the complete answer paper.

b

Discuss the future prospective in pharmacogenomics.

5 marks

Answer

Sign in to view the complete answer paper.

About this paper

This page contains the question paper of PHARMACOVIGILANCE from JAWAHARLAL NEHRU TECHNOLOGICAL UNIVERSITY HYDERABAD for B.Pharmacy IV Year I, June/July - 2024, R17.

For the solved question paper with answers, switch to the Answer Paper tab.

Other papers in PHARMACOVIGILANCE

Loading Question Papers

Fetching data from database...